

Published in final edited form as:

Artery Res. 2008 November ; 2(4): 138–147. doi:10.1016/j.artres.2008.09.002.

## A cardiovascular phenotype in warfarin-resistant *Vkorc1* mutant rats

Michael H. Kohn<sup>1</sup>, Roger E. Price<sup>2</sup>, and Hans-Joachim Pelz<sup>3</sup>

<sup>1</sup>Department of Ecology & Evolutionary Biology, Institute of Biosciences and Bioengineering, Rice University, MS 170, 6100 Main Street, Houston, Texas 77005, U.S.A.

<sup>2</sup>Comparative Pathology Laboratory, Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030, U.S.A.

<sup>3</sup>Federal Research Centre for Cultivated Plants - Julius Kuehn-Institute, Vertebrate Research, Toppeideweg 88, 48161 Münster, Germany

### Summary

**Background**—The inhibition of the vitamin K cycle by warfarin promotes arterial calcification in the rat. Conceivably, genetically determined vitamin K-deficiency owing to a mutant epoxide reductase subcomponent 1 (*Vkorc1*) gene, a key component of the vitamin K cycle, might also promote arterial calcification. In the absence of an available *Vkorc1* gene knockout model we used a wild-derived *Vkorc1* mutant rat strain (*Rattus norvegicus*) to explore the validity of this hypothesis.

**Methods**—We provide histopathological descriptions of a naturally occurring *Vkorc1* gene knockdown: wild-derived lab-reared rats that are resistant to the anticoagulant warfarin owing to a non-synonymous mutation in the *Vkorc1* gene (*Vkorc1*<sup>Y->C</sup>), which, *in vitro*, reduces the basal activity of the vitamin K epoxide reductase enzyme complex by ~52%. H&E stained sections of heart and kidney were compared between homozygous *Vkorc1*<sup>Y->C/Y->C</sup>, heterozygous *Vkorc1*<sup>Y->C/+</sup> and wildtype *Vkorc1*<sup>+/+</sup> rats of both sexes.

**Results**—We observed that the aorta of the heart was mineralized in the *Vkorc1*<sup>Y->C/Y->C</sup> male rats but lesions were virtually absent from *Vkorc1*<sup>Y->C/+</sup> and *Vkorc1*<sup>+/+</sup> male and all female rats. The renal arteries were mineralized in *Vkorc1*<sup>Y->C/Y->C</sup> and *Vkorc1*<sup>Y->C/+</sup> mutant rats, regardless of sex.

**Conclusions**—Results support a hypothesis that posits that *Vkorc1* genetic polymorphisms reducing basal enzyme activity could affect cardiovascular health, with dependencies on genotype, sex, and tissue. The undercarboxylation of the vitamin K-dependent Matrix Gla protein may be the crucial component of the pathway promoting this mineralization.

### Keywords

Aorta; mineralization; renal artery; urolith; vitamin K epoxide reductase; warfarin

---

Correspondence: Department of Ecology & Evolutionary Biology, Institute of Biosciences and Bioengineering, Rice University, MS 170, 6100 Main Street, Houston, Texas 77005, U.S.A., hmkohn@rice.edu.

**Disclosures** The authors confirm that there is no conflict of interest to disclose.

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

## Introduction

The understanding of the chemical nature of vitamin K antagonists and their connections to the vitamin K cycle, as well as the long history spanning the efforts of the biochemical purification, genetic mapping, and molecular cloning of the vitamin K-2,3 epoxide reductase protein complex VKOR,<sup>1-10</sup> have culminated in the identification of a gene, now named vitamin K epoxide reductase subunit 1, *Vkorc1*.<sup>11, 12</sup> The *Vkorc1* encodes a warfarin-sensitive protein that could in fact be the key enzyme, or rather, part of the key enzyme complex VKOR, of the vitamin K cycle.<sup>13</sup> The gene appears to be responsible for vitamin K epoxide reduction to the active vitamin KH<sub>2</sub> cofactor for the  $\gamma$ -carboxylase. The  $\gamma$ -carboxylase is responsible for the post translational  $\gamma$ -carboxylation of vitamin K-dependent proteins, notably blood coagulation factors and Matrix Gla protein MGP.<sup>14, 15</sup>

The vitamin K cycle is appreciated for its role in blood coagulation.<sup>14, 16</sup> In this context the vitamin K cycle is of therapeutic relevance because it can be inhibited by the oral anticoagulant drug warfarin.<sup>15</sup> This application of warfarin is an area where the value of personalized medicine is under investigation by analyzing *Vkorc1* genetic polymorphisms to predict warfarin dosing in human study cohorts.<sup>17-20</sup> Mutations in the *Vkorc1* gene were found to be associated with a rare severe bleeding phenotype in humans.<sup>21</sup>

The vitamin K cycle may mediate processes more generally related to cardiovascular health.<sup>14,23-28</sup> For example, inhibition of the VKOR by warfarin in the extra-hepatic tissues of laboratory rats resulted in the mineralization of the aorta.<sup>29-31</sup> Inhibition of the VKOR influences downstream processes with dependencies on vitamin K as a co-factor for the  $\gamma$ -carboxylation of proteins, notably MGP.<sup>27, 32</sup> MGP is an important inhibitor of vessel and cartilage calcification that is expressed in human calcified atherosclerotic plaques.<sup>33-40</sup> Arterial calcification could be accelerated by oral anticoagulant therapy, as mediated by the inhibition of the VKOR by warfarin and the resulting undercarboxylation of MGP.<sup>20,41</sup> Genetic polymorphisms in the MGP have been shown to affect cardiovascular health.<sup>42</sup> Thus, conceivably, genetic polymorphisms in the *Vkorc1* gene also might affect cardiovascular health.<sup>43</sup>

Warfarin is also used as a rodent poison.<sup>16</sup> Numerous wild populations of rodents have evolved resistance to warfarin.<sup>44</sup> In rat *Rattus norvegicus* populations in Germany, where our wild-derived rats were collected, there is near complete association between a mutated *Vkorc1* and warfarin resistance, which led the authors to propose that the *Vkorc1* mutation forms the molecular genetic basis of warfarin resistance.<sup>22,45</sup> Warfarin resistance is under natural selection in free-living rat populations because the carriers of the mutation are at an advantage over the wildtype on farms and in townships where warfarin is used.<sup>46-49</sup> However, this advantage of resistance may be offset by some pleiotropic fitness cost related to vitamin K deficiency.<sup>50,51</sup> Typically, this cost is thought to be due to vitamin K deficiency and lethal hemorrhage restricted to the homozygous mutant rats.<sup>52</sup> This scenario lead to the conclusion that warfarin resistance generally is under overdominant natural selection, i.e. both the warfarin-resistant and warfarin-susceptible homozygous genotypes have lower fitness relative to the warfarin-resistant heterozygous genotype.<sup>47, 53, 54</sup>

Here we examined warfarin-resistant rats for the phenotypic effects of a naturally occurring gene knockdown mutation in the *Vkorc1*, and thus, we bypass the current lack of a *Vkorc1* gene knockout model. We tested the hypothesis that warfarin resistance might have consequences to vitamin K-dependent processes that are independent of the effects on blood coagulation. The central argument is that the recycling of vitamin K in mutant strains resistant to the vitamin K antagonist warfarin is itself inefficient due to the altered *Vkorc1*, leading to a relative vitamin K-deficient state in the warfarin resistant rat compared to wildtype rats. This relative vitamin

K deficiency should lead to an undercarboxylation of vitamin K-dependent proteins, notably the potent inhibitor of vascular mineralization MGP, thereby promoting vessel calcification.

## Methods

### Rat strains

This study was conducted on rats sampled from an area in Northwestern Germany.<sup>22,45,55,56</sup> Rats from this area carry a non-synonymous mutation in the *Vkorc1* gene from A to G, resulting in the tyrosine to cysteine (Y to C) amino-acid change at position 139 in exon 3. This amino-acid change results in a 47% reduction of the basal *in vitro* *Vkorc1* activity.<sup>11,22,57</sup> The *Vkorc1* genotypes are designated as *Vkorc1*<sup>Y->C/Y->C</sup> (homozygous mutant), *Vkorc1*<sup>Y->C/+</sup> (heterozygous mutant) and *Vkorc1*<sup>+/+</sup> (wildtype). The strain examined is resistant to the anticoagulant warfarin if *Vkorc1*<sup>Y->C/Y->C</sup> or *Vkorc1*<sup>Y->C/+</sup>, i.e. the mutation is dominant with respect to warfarin resistance (but is of incomplete penetrance<sup>58</sup>).

Rats were trapped in the field and were kept in the laboratory for the months specified as age in supplementary table 1 (which thus is an underestimate of the age of those rats), or rats were born by wild-caught rats in the laboratory and were of the given age in supplementary table 1. Rats were kept in Macrolon® cages on shavings from saw mills with tap water and standard lab food (altromin® 1324) *ad lib*. The diet contained 3 mg/kg Vitamin K3. The Institutional Animal Care and Use Committee approved the study.

The warfarin resistant (RW) and warfarin-susceptible (RW+) phenotypes were distinguished by using a blood clotting response test (BCR) that measured percent clotting activities (PCA) after injection of a diagnostic dose of warfarin<sup>22,55</sup> (c.f. Rodenticide Resistance Action Committee 2003, a reappraisal of blood clotting response tests for anticoagulant resistance and a proposal for a standardized BCR test methodology: Technical Monograph, Crop Life International). Male and female rats were induced with 7mg/kg or 8.5mg/kg warfarin, respectively, by intraperitoneal injection, which corresponds to 4 multiples of the ED<sub>50</sub> in susceptible rats. This treatment unlikely explains the systematic differences among genotypes described in the results section as all genotypes were subjected to it. The presence of the A to G mutation at position 139 in exon 3 of the *Vkorc1* gene was confirmed by PCR as described.<sup>22</sup>

### Histology

The aorta and kidney were harvested and preserved by immersion in 10% buffered formalin. Tissues underwent conventional processing and resulting paraffin sections were stained with hematoxylin and eosin (H&E). Specialized stains for calcium with Von Kossa and Alizarin red were repeated multiple times with no positive result. The diagnosis of mineralization in this exploration study was therefore made entirely based on the characteristic appearance of the mineralization after H&E staining. The cause of the inability to confirm the presence of mineral in the tissue using special staining techniques was not determined, but there clearly is a need to specifically identify the chemical nature of this mineralization during future analyses. We note that our rats showed diffuse signs of postmortem autolysis because they went through freeze-thaw cycles during transport. However, it is not clear how this could have resulted in systematic differences in mineralization between *Vkorc1* genotypes during our study. Slides listed in supplementary table 1 are available from M.H.K. for inspection.

Initially, evaluation of histological sections focused on the presence or absence of mineralization as judged by R.E.P during a blind test, i.e. in the absence of information on sex, phenotype, and genotype. Subsequently, histological sections were reviewed with respect to potential miss-classifications during the blind test. During this informed secondary review a

fuller description of the nature and degree of lesions was compiled. Finally, to improve our ability to evaluate the best model describing the data and to gauge the importance of potentially worrisome parameters (see below), we attached arbitrarily scaled numerical ordinal scores to the degree of mineralization: 0 for absence and 1, 2, and 3-4 for minimal, modest, and marked levels of mineralization, respectively.

### Statistical analysis

Nominal logistic regression as implemented in the J<sub>MP</sub> I<sub>N</sub> software package (Cengage Learning, Florence, KY) was applied to the presence/absence scores of the blind testing and of the secondary review. Stepwise regression was used to screen the parameters sex, origin, age, phenotype, and genotype listed in supplementary table 1 for individual significance (judged at  $\alpha=0.05$ ). The best model incorporating significant parameters and their interaction terms was used to re-evaluate statistical significance during linear regression and analysis of variance (ANOVA). Potentially worrisome parameters specifically examined for their effect were the variable age of rats and the origin of rats (caught in the wild and raised in the laboratory or born by wild-caught rats raised in the laboratory).

## Results

### Aorta

A cardiovascular phenotype detected by H&E staining on histological sections was manifest as mineralization in the aorta of the heart and of the branching arteries, usually found to be focal to multifocal coalescing. It typically occurred in the adventitia of the aorta and in the tunica media and adventitia at the intersection of the branching artery with the aorta (Figures 1 and 2).

**Effect of warfarin-resistance phenotype and gender**—Mineralization was found present in 4 of the 8 and 5 of the 8 warfarin-resistant (RW) male rats during the blind test and after secondary review, respectively (Table 1). All 4 warfarin-susceptible (RW+) males were classified as free of mineralization during the blind test and secondary review. Mineralization was absent or minimal in RW and RW+ females (Table 1).

**Effect of warfarin-resistance genotype and gender**—Four out of 5 *Vkorc1*<sup>Y->C/Y->C</sup> male rats displayed signs of mineralization during the blind test, and all 5 *Vkorc1*<sup>Y->C/Y->C</sup> male rats displayed minimal to marked signs of mineralization after secondary review (Table 1). In contrast, none of the 3 *Vkorc1*<sup>Y->C/+</sup> and 4 *Vkorc1*<sup>+/+</sup> males and all females were judged free of mineralization. However, 2 *Vkorc1*<sup>Y->C/Y->C</sup> female rats displayed minimal signs of mineralization during secondary review (Table 1).

A statistical model incorporating the parameters sex, genotype and their interaction term explained ~79% of the variation in the response variable ‘presence or absence’ of mineralization (nominal logistic regression,  $\chi^2=21.2$ , d.f. 5,  $p=0.0007$ ). We were concerned that the worrisome parameters origin and age of rats would have an effect on results. We conducted stepwise regression on a prior model that incorporated all parameters, including age and origin, as well as the possible interaction terms. Only sex ( $p=0.003$ ), genotype ( $p<0.001$ ) and their interaction term ( $p=0.007$ ) were significant. The model incorporating these parameters was significant (ANOVA,  $R^2=75.1\%$ , d.f. 3,  $F_{\text{ratio}} 17.5$ ,  $p<0.0001$ ). Age ( $p=0.712$ ) and origin ( $p=0.452$ ) were not significant individually or when part of an interaction term.

Overall, male sex and warfarin-resistance genotype primarily determine the mineralization of the aorta in our rat strain, and the *Vkorc1* mutation appears to be recessive with respect to the mineralization of the aorta (Figure 3).

## Renal arteries

Warfarin resistance phenotype and genotype determined the mineralization of the renal arteries of the kidney, however a sex-specific effect was not detected (Figure 3). If present, the mineralization generally was multifocal coalescing of the endothelial surface of the renal arteries exiting the kidney (predominantly in the heterozygous genotype) and, the renal arteries inside the kidney in some samples with full mineralization of the arterial wall (predominantly in the homozygous mutant genotype) (Figures 4 and 5). Uroliths were seen in 3 female rats, two of which were *VkorcI*<sup>Y->C/+</sup> and one was *VkorcI*<sup>Y->C/Y->C</sup> (c.f. Figure 4).

**Effect of warfarin-resistance phenotype and gender**—Mineralization was assessed as present in 6 of the 8 and 7 of the 8 RW male rats during the blind test and after secondary review, respectively (Table 2). In contrast, all 4 RW+ males were free of signs of mineralization. Mineralization was also found present in all 6 and 5 of the 6 RW female rats during the blind test and after secondary review, respectively (Table 2). All 3 RW+ females were free of signs of mineralization or, upon secondary review, 1 of the 3 was judged to display minimal lesions.

**Effect of warfarin-resistance genotype and gender**—All 5 RW male rats with the *VkorcI*<sup>Y->C/Y->C</sup> mutation displayed moderate to marked signs of mineralization (Table 2). Of the 3 *VkorcI*<sup>Y->C/+</sup> males 1 and 2 showed signs of mineralization during the blind test and after secondary review, respectively. After secondary review 2 warfarin-resistant female rats homozygous for the *VkorcI*<sup>Y->C/Y->C</sup> mutation were judged to display minimal signs of mineralization (Table 2).

A statistical model incorporating genotype explained ~55% of the variation in the response variable ‘presence or absence’ of mineralization (nominal logistic regression,  $\chi^2=15.4$ , d.f. 2,  $p=0.0004$ ). In addition, stepwise regression on a prior model that incorporated all parameters and interaction terms showed that only genotype ( $p<0.0001$ ) and age ( $p=0.014$ ) emerged as significant parameters. The model incorporating these was significant (ANOVA,  $R^2=77.4\%$ , d.f. 2,  $F_{ratio}$  30.8,  $p<0.0001$ ). Importantly, a comparison of the *VkorcI*<sup>Y->C/Y->C</sup> and *VkorcI*<sup>Y->C/+</sup> genotypes, which did not differ in age ( $p=0.303$ , Wilcoxon/Kruskal-Wallis Rank Sums Test) showed that these were significantly different in the mineralization (Figure 3,  $p=0.012$ , Wilcoxon/ Kruskal-Wallis Rank sums Test), suggesting age is not a parameter that can explain the mineralization fully.

Overall, warfarin resistance phenotype explains the degree of mineralization of the renal arteries well, and the *VkorcI*<sup>Y->C</sup> mutation is co-dominant (Figure 3). The effect of age merits closer investigation during future studies.

## Discussion

In this pilot study we reported on a cardiovascular phenotype in wild-derived warfarin resistant rats from Germany that carry an A to G mutation at position 416 in the *VkorcI* transcript, resulting in a Y to C amino-acid change at position 139 in the protein.<sup>11,22,45,57</sup> The genotypes *VkorcI*<sup>Y->C/Y->C</sup>, *VkorcI*<sup>Y->C/+</sup>, both warfarin resistant, RW, and the warfarin susceptible (RW +) genotype *VkorcI*<sup>+/+</sup> were compared for their cardiovascular phenotypes (Tables 1 and 2). The reason for using wild-derived warfarin resistant rats having the *VkorcI* mutations is the lack of an available *VkorcI* gene knockout in an inbred rodent strain, which would have been a better experiment.

The phenotypes examined were concerned with the mineralization of the aorta and of the renal arteries as deduced from H&E stained histological sections. We observed mineralization of the aorta predominantly in the homozygous warfarin-resistant male rats. Mineralization in the



renal arteries appeared in both sexes almost exclusively in warfarin-resistant genotypes. The finding of uroliths is in agreement with the expression of vitamin K dependent proteins, including MGP, in urolithiasis<sup>59</sup>, but owing to the small number of observations should be interpreted with caution.

We suggest that the observed phenotypes are due to a ~53% reduction of the basal *VKOR* enzyme *in vitro* activity in the *Vkorc1*<sup>Y>C/Y>C</sup> genotype compared to the *Vkorc1*<sup>+/+</sup> genotype.<sup>11,22,45,57</sup> Conceivably, the *Vkorc1*<sup>Y>C/+</sup> mutant rat should have an ~25% reduced *VKOR* activity, i.e. that the mutation is co-dominant with respect to *VKOR* activity in the warfarin-unchallenged state. This may be a valid assumption, because in the warfarin-challenged state the homozygous mutant rat has ~87% of *in vitro* *VKOR* activity while the heterozygote has about half of that (~42%), suggesting warfarin-resistance alleles are co-dominant with incomplete penetrance.<sup>58</sup>

Our results support the hypothesis that warfarin resistance in rats might have physiological consequences to vitamin K-dependent processes that are independent of the effects on blood coagulation. Specifically, the recycling of vitamin K in warfarin-resistant rats is itself inefficient due to the altered *Vkorc1* subunit, leading to relative vitamin K-deficiency in the warfarin-unchallenged state. This relative vitamin K deficiency is expected to result in the undercarboxylation of vitamin K-dependent proteins that play a role in arterial calcification, foremost MGP.

To confirm vitamin K-deficiency *in vivo* future work should measure *VKOR* activity in individual rats in the warfarin-unchallenged state. Moreover, to obtain a good measure for vitamin K recycling capacity it would be desirable to measure the hepatic- and/or blood vitamin K 2,3-epoxide to vitamin K ratio. To implicate the MGP pathway in the pleiotropic effects of warfarin resistance histochemical measures of carboxylated and undercarboxylated MGP are needed.<sup>23</sup> In general, a more exhaustive phenotyping of the *Vkorc1* mutant rat during future studies seems to be warranted now. Finally, to eliminate concerns that the observed pattern is due to genetic background our study should be replicated in strains where only the *Vkorc1* gene carrying a mutation has been introgressed into laboratory strains.

Our results should be interpreted with respect to the particular mutation and strain under study. First, owing to the outbred genetic background of rats we caution that genetic polymorphisms linked to the *Vkorc1*, or in downstream biochemical pathways, may have contributed to the observed effects. It is known that strain-specific modifier loci, some sex-specific, affect the warfarin resistance profile<sup>58,60-62</sup> and, conceivably, other phenotypes, including the mineralization of the cardiovascular system. Second, it is possible that other mutations in the *Vkorc1* gene differ in their expression of the cardiovascular phenotypes. Finally, it should be noted that for our rat strain from Germany dietary vitamin K requirements were not found to be measurably elevated during a pilot survey (H-J Pelz, pers. observation). The functional elimination of the *VKOR* might boost the up-regulation of other pathways for the recruitment of vitamin KH<sub>2</sub>, resulting in the maintenance of hepatic levels of vitamin K needed to maintain blood coagulation.<sup>55</sup> However, our study is inconsistent with the ability of such pathways, if applicable, to compensate for extrahepatic vitamin K deficiency resulting in the cardiovascular phenotypes.

With the caveats mentioned above in mind our study should be of interest to the biomedical field by showing a plausible histological cardiovascular phenotype associated with a *Vkorc1* polymorphism. Support for such an association has relied on human studies. Given the complex genetic architecture of cardiovascular health and environmental influences in human additional evidence from a rodent model was needed. Our study now provides such support for an association of *Vkorc1* mutations and cardiovascular mineralization. Assuming that our results

are portable to the human condition, we suggest that genetic variation in the *Vkorc1*, and subtle variations in vitamin K cycling over the lifetime of human subjects, are factoring into the mineralization of the aorta and of the renal arteries.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

This work was funded in part by a Hamill innovation grant to MHK and Michael Liebschner from the Institute of Biosciences and Bioengineering, Rice University and by grant R01 HL091007 from the National Heart, Lung, and Blood Institute (NHLBI) to MHK. We are thankful for our discussions with Michael Liebschner and for the comments made by anonymous reviewers.

**Grant support:** Hamill Innovation grant; National Heart, Lung, and Blood Institute (NHLBI)

## References


1. Stahmann MA, Huebner CF, Link KP. Studies on the hemorrhagic sweet clover disease. V. Identification and synthesis of the hemorrhagic agent. *J Biol Chem* 1941;138(5):513–27.
2. Boyle CM. Case of apparent resistance of *Rattus norvegicus* Berkenhout to anticoagulant poisons. *Nature* 1960;188:517.
3. Lund M. Resistance to warfarin in common rat. *Nature* 1964;203(494):778–&. [PubMed: 14207298]
4. Greaves JH, Ayres P. Heritable resistance to warfarin in rats. *Nature* 1967;215(5103):877–8. [PubMed: 6049747]
5. Bell RG, Caldwell PT. Mechanism of warfarin resistance - metabolism of vitamin-K1. *Biochem* 1973;12(9):1759–62. [PubMed: 4699235]
6. Fasco MJ, Hildebrandt EF, Suttie JW. Evidence that warfarin anticoagulant action involves two distinct reductase activities. *J Biol Chem* 1982;257(19):11210–2. [PubMed: 6811577]
7. Hildebrandt EF, Preusch PC, Patterson JL, Suttie JW. Solubilization and characterization of vitamin K epoxide reductase from normal and warfarin-resistant rat liver microsomes. *Arch Biochem Biophys* 1984;228(2):480–92. [PubMed: 6696443]
8. MacNicol AD. A comparison of warfarin resistance and liver microsomal vitamin K epoxide reductase activity in rats. *Biochim Biophys Acta* 1985;840(1):13–20. [PubMed: 3995080]
9. Kohn MH, Pelz JH. Genomic assignment of the warfarin resistance locus, *Rw*, in the rat. *Mamm Genome* 1999;10(7):696–8. [PubMed: 10384042]
10. Kohn MH, Pelz HJ. A gene-anchored map position of the rat warfarin-resistance locus, *Rw*, and its orthologs in mice and humans. *Blood* 2000;96(5):1996–8. [PubMed: 10961907]
11. Rost S, Fregin A, Ivaskevicius V, et al. Mutations in *Vkorc1* cause warfarin resistance and multiple coagulation factor deficiency type 2. *Nature* 2004;427(6974):537–41. [PubMed: 14765194]
12. Li T, Chang CY, Jin DY, Lin PJ, Khvorova A, Stafford DW. Identification of the gene for vitamin K epoxide reductase. *Nature* 2004;427(6974):541–4. [PubMed: 14765195]
13. Wallin R, Hutson SM. Warfarin and the vitamin K-dependent gamma-carboxylation system. *Trends In Mol Medicine* 2004;10(7):299–302.
14. Stafford DW. The vitamin K cycle. *J of Thromb and Haemost* 2005;3(8):1873–8. [PubMed: 16102054]
15. Suttie JW. Warfarin and vitamin-K. *Clin Cardiology* 1990;13(4):16–8.
16. Scully MF. Warfarin therapy: rat poison and the prevention of thrombosis. *The Biochemist* 2002;24:15–7.
17. D'Andrea G, D'Ambrosio RL, Di Perna P, et al. A polymorphism in the *Vkorc1* gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. *Blood* 2005;105(2):645–9. [PubMed: 15358623]

18. Li T, Lange LA, Li X, et al. Polymorphisms in the *Vkorc1* gene are strongly associated with warfarin dosage requirements in patients receiving anticoagulation. *J of Med Genet* 2006;43(9):740–4. [PubMed: 16611750]
19. Gage BF, Lesko LJ. Pharmacogenetics of warfarin: regulatory, scientific, and Clin issues. *J of Thromb and Thrombol* 2008;25:45–51.
20. Schurgers LJ, Aebert H, Vermeer C, Bultmann B, Janzen J. Oral anticoagulant treatment: friend or foe in cardiovascular disease? *Blood* 2004;104(10):3231–2. [PubMed: 15265793]
21. Fregin A, Rost S, Wolz W, Krebsova A, Muller CR, Oldenburg J. Homozygosity mapping of a second gene locus for hereditary combined deficiency of vitamin K-dependent clotting factors to the centromeric region of chromosome 16. *Blood* 2002;100(9):3229–32. [PubMed: 12384421]
22. Pelz HJ, Rost S, Hunerberg M, et al. The genetic basis of resistance to anticoagulants in rodents. *Genetics* 2005;170(4):1839–47. [PubMed: 15879509]
23. Schurgers LJ, Dissel PEP, Spronk HMM, et al. Role of vitamin K and vitamin K-dependent proteins in vascular calcification. *Z f Kardiol* 2001;90(Suppl 3):III/57–III/63.
24. Price PA, Faus SA, Williamson MK. Warfarin-induced artery calcification is accelerated by growth and vitamin D. *Arterioscl Thromb and Vasc Biol* 2000;20(2):317–27. [PubMed: 10669626]
25. Shearer MJ. Role of vitamin K and Gla proteins in the pathophysiology of osteoporosis and vascular calcification. *Curr Opin Clin Nutr Metab Care* 2000;3(6):433–8. [PubMed: 11085828]
26. Price PA, Buckley JR, June HH, Williamson MK. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. *J of Bone and Mineral Res* 2001;16:S157–8.
27. Wallin R, Wajih N, Greenwood GT, Sane DC. Arterial calcification: A review of mechanisms, animal models, and the prospects for therapy. *Medic Res Rev* 2001;21(4):274–301.
28. Erkkila AT, Booth SL. Vitamin K intake and atherosclerosis. *Curr Opin Lipidol* 2008;19:39–42. [PubMed: 18196985]
29. Price PA, Faus SA, Williamson MK. Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. *Arterioscler Thromb Vasc Biol* 1998;18(9):1400–7. [PubMed: 9743228]
30. Howe AM, Webster WS. Warfarin exposure and calcification of the arterial system in the rat. *Intl J Exp Path* 2000;81(1):51–6.
31. Price PA, Patel R, Alagao FC. Matrix Gla protein specifically inhibits calcification of human aortic elastin *in vitro*. *Arteriosclerosis Thromb Vasc Biol* 2001;21(4):703–8.
32. Shanahan CM, Proudfoot D, Farzaneh-Far A, Weissberg PL. The role of Gla proteins in Vasc calcification. *Crit Rev Eukar Gene Expr* 1998;8(34):357–75.
33. Alagao FC, Patel R, Price PA. Matrix Gla protein specifically inhibits calcification of human aortic elastin *in vitro*. *J of Bone and Mineral Res* 2000;15:S208–S.
34. Bostrom K, Demer LL. Regulatory mechanisms in Vascular calcification. *Crit Rev Eukar Gene Expr* 2000;10(2):151–8.
35. Braam L, Dissel P, Gijsbers B, et al. Assay for human matrix Gla protein in serum - potential applications in the cardiovascular field. *Arterioscl Thromb Vasc Biol* 2000;20(5):1257–61. [PubMed: 10807741]
36. Canfield AE, Doherty MJ, Kelly V, et al. Matrix Gla protein is differentially expressed during the deposition of a calcified matrix by Vasc pericytes. *Febs Lett* 2000;487(2):267–71. [PubMed: 11150522]
37. Wallin R, Cain D, Hutson SM, Sane DC, Loeser R. Modulation of the binding of matrix Gla protein (MGP) to bone morphogenetic protein-2 (BMP-2). *Thromb and Haemost* 2000;84(6):1039–44. [PubMed: 11154111]
38. Dhore CR, Cleutjens JPM, Lutgens E, et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. *Arteriosclerosis Thromb and Vasc Biol* 2001;21(12):1998–2003.
39. Farzaneh-Far A, Weissberg PL, Proudfoot D, Shanahan CM. Transcriptional regulation of matrix gla protein. *Z Kardiol* 2001;90 Suppl 3:38–42. [PubMed: 11374031]
40. Wang Y, Bostrom KI. Matrix GLA protein binds bone morphogenetic protein-2, possible mechanism in vascular calcification. *Arterioscl Thromb and Vasc Biol* 2001;21(4):702–8.
41. Whittaker P, Donovan JL, Przyklenk K. Long-term warfarin therapy is associated with tissue calcification. *J of Thromb and Thrombol* 2008;25:125–8.




42. Herrmann SM, Whatling C, Brand E, et al. Genetic polymorphisms in the matrix Gla protein are associated with calcification, atherosclerosis and myocardial infarction. *Nieren Hochdruckkrankheiten* 2001;30(5):193–5.
43. Wang YB, Zhang WL, Zhang YH, et al. VKORC1 haplotypes are associated with arterial vascular diseases (stroke, coronary heart disease, and aortic dissection). *Circulation* 2006;113(12):1615–21. [PubMed: 16549638]
44. Jackson, WB. Pesticide resistance strategies and tactics for management. Natl Academy Press; Washington D.C.: 1986. Case histories of anticoagulant resistance.
45. Pelz HJ, Rost S, Muller CR. DNA-based field monitoring of warfarin resistance in rats (*Rattus norvegicus*). *Intl J Pest Managem* 2007;53:281–4.
46. Bishop JA, Hartley DJ, Partridge GG. Population-dynamics of genetically determined resistance to warfarin in *Rattus norvegicus* from Mid Wales. *Heredity* 1977;39(12):389–98. [PubMed: 272364]
47. Partridge GG. Relative fitness of genotypes in a population of *Rattus norvegicus* polymorphic for warfarin resistance. *Heredity* 1979;43(10):239–46. [PubMed: 295047]
48. Berdoy M, Smith P. Arms-race and rat race - Adaptations against poisoning in the brown rat. *Rev d Ecol-la Terre et la Vie* 1993;48(2):215–28.
49. Kohn MH, Pelz HJ, Wayne RK. Natural selection mapping of the warfarin-resistance gene. *Proc Natl Acad Sci USA* 2000;97(14):7911–5. [PubMed: 10884423]
50. Greaves JH, Ayres PB. Unifactorial inheritance of warfarin resistance in *Rattus norvegicus* from Denmark. *Genet Res* 1977;29(3):215–22. [PubMed: 892442]
51. Smith P, Townsend MG, Smith RH. A cost of resistance in the brown rat - reduced growth-rate in warfarin-resistant lines. *Functional Ecol* 1991;5(3):441–7.
52. Partridge GG. The vitamin-K requirements of wild Brown rats (*Rattus norvegicus*) resistant to warfarin. *Comp Biochem Physiol* 1980;66(1):3–7.
53. Greaves JH, Redfern R, Ayres PB, Gill JE. Warfarin resistance - balanced polymorphism in Norway rat. *Genet Res* 1977;30(3):257–63.
54. Smith P, Berdoy M, Smith RH. Body-weight and social dominance in anticoagulant resistant rats. *Crop Prot* 1994;13(4):311–5.
55. Pelz HJ, Hanisch D, Lauenstein G. Resistance to anticoagulant rodenticides in Germany and future strategies to control *Rattus norvegicus*. *Pest Sci* 1995;43(1):61–7.
56. Pelz HJ, Klemann N. Rat control strategies in organic pig and poultry production with special reference to rodenticide resistance and feeding behaviour. *Njas-Wageningen J Life Sci* 2004;52(2): 173–84.
57. Rost S, Fregin A, Hunerberg M, Bevans CG, Muller CR, Oldenburg J. Site-directed mutagenesis of coumarin-type anticoagulant-sensitive VKORC1 - Evidence that highly conserved amino acids define structural requirements for enzymatic activity and inhibition by warfarin. *Thromb and Haemost* 2005;94(4):780–6. [PubMed: 16270630]
58. Kohn MH, Pelz HJ, Wayne RK. Locus-specific genetic differentiation at Rw among warfarin-resistant rat (*Rattus norvegicus*) populations. *Genetics* 2003;164(3):1055–70. [PubMed: 12871915]
59. Yasui T, Fujita K, Sasaki S, et al. Expression of bone matrix proteins in urolithiasis model rats. *Urol Res* 1999;27(4):255–61. [PubMed: 10460895]
60. Greaves JH, Ayres PB. Multiple allelism at the locus controlling warfarin resistance In the Norway rat. *Genet Res* 1982;40(1):59–64. [PubMed: 7141222]
61. Smith P, Berdoy M, Smith RH, Macdonald DW. A new aspect of warfarin resistance in wild rats - benefits in the absence of poison. *Functional Ecol* 1993;7(2):190–4.
62. Markussen MDK, Heiberg AC, Nielsen R, Leirs H. Vitamin K requirement in Danish anticoagulant-resistant Norway rats (*Rattus norvegicus*). *Pest Managem Sci* 2003;59(8):913–20.






**Figure 1.** Photomicrographs of H&E stained sections under 40X magnification (50 µm resolution) of histological sections of the aorta from male rats. **(A-E)** *Vkorc1*<sup>Y->CY->C</sup> warfarin-resistant male rats. **(F-H)** *Vkorc1*<sup>Y->C/+</sup> heterozygous warfarin-resistant rats. **(I-L)** *Vkorc1*<sup>+/+</sup> warfarin-susceptible rats. V=lumen, W=wall of aorta. C.f. supplement 1 for full description of slides.






**Figure 2.** Photomicrographs of H&E stained sections under 40X magnification (50  $\mu\text{m}$  resolution) of histological sections of the aorta from female rats. (A-D) *Vkorc1*<sup>Y->C/Y->C</sup> warfarin-resistant female rats. (E-F) *Vkorc1*<sup>Y->C/+</sup> heterozygous warfarin-resistant rats. (G-I) *Vkorc1*<sup>+/+</sup> warfarin-susceptible rats. C.f. legend to Fig. 1.



**Figure 3.**


The average score assigned to the degree of mineralization of the aorta and of the renal arteries of male and female rats in the warfarin-resistant and warfarin susceptible *Vkorc1* mutant genotypes. Note that the scaling of scores was arbitrary and in relation to slides of the same tissue only, such that the score between aorta and renal arteries, though shown side-by-side here, should not be directly compared. Note also that the average score of the mineralization of the aorta in homozygous female rats was 0.5 whereas in males the score was 1.8 (see text).





**Figure 4.** Photomicrographs of H&E stained sections under 40X magnification (50  $\mu\text{m}$  resolution) of histological sections of the renal arteries from male rats. (A-E) *Vkorc1*<sup>Y->CY->C</sup> warfarin-resistant male rats. (F-H) *Vkorc1*<sup>Y->C/+</sup> heterozygous warfarin-resistant rats. (I-L) *Vkorc1*<sup>+/+</sup> warfarin-susceptible rats. Arrows depict mineralization. T= tubules, V=lumen of the renal arteries, M=macula, X= juxtaglomerula. C.f. supplement 1 for full description of slides.





**Figure 5.** Photomicrographs of H&E stained sections under 40X magnification (50  $\mu\text{m}$  resolution) of histological sections of the renal arteries from female rats. (A-D) *Vkorc1*<sup>Y->C/Y->C</sup> warfarin-resistant female rats. (E-F) *Vkorc1*<sup>Y->C/+</sup> heterozygous warfarin-resistant rats. (G-I) *Vkorc1*<sup>+/+</sup> warfarin-susceptible rats. C.f. legend to Fig. 3.

Scoring of mineralization as present or absent in histological sections of the male and female aorta during blind test (first number) and after secondary review (second number).

Table 1

Sex	Phenotypes and genotypes	Present	Absent	Description	Average score (range)	Total
<b>Males:</b>	RW	4/5	4/3	None to marked lesions	1.1 (0-3)	8
	<i>Vkorc1</i> <sup>Y-&gt;CY-&gt;C</sup>	4/5	1/0	Minimal to marked lesions	1.8 (1-3)	5
	<i>Vkorc1</i> <sup>Y-&gt;C+</sup>	0/0	3/3	No lesions	0	3
	RW+ ( <i>Vkorc1</i> <sup>+/+</sup> )	0/0	4/4	No lesions	0	4
	Subtotals (N=)	4/5	8/7	-	-	12
<b>Females:</b>	RW	0/2	6/4	None to minimal lesions	0.3 (0-1)	6
	<i>Vkorc1</i> <sup>Y-&gt;CY-&gt;C</sup>	0/2	4/2	None to minimal lesions	0.5 (0-1)	4
	<i>Vkorc1</i> <sup>Y-&gt;C+</sup>	0/0	2/2	No lesions	0	2
	RW+ ( <i>Vkorc1</i> <sup>+/+</sup> )	0/0	3/3	No lesions	0	3
	Subtotals (N=)	0/2	9/7	-	-	9

RW and RW+ designate the homozygous (*Vkorc1*<sup>Y->CY->C</sup>) and heterozygous (*Vkorc1*<sup>Y->C/+</sup>) warfarin-resistant and warfarin-susceptible phenotype, respectively.

Table 2

Scoring of mineralization as present or absent in histological sections of the male and female renal arteries.

Sex	Phenotypes and genotypes	Present	Absent	Description	Average score (range)	Total
<b>Males:</b>	RW	6/7	2/1	None to marked lesions	2.4 (0-4)	8
	<i>Vkorc1</i> <sup>Y-&gt;CY-&gt;C</sup>	5/5	0/0	Moderate to marked lesions	3.2 (2-4)	5
	<i>Vkorc1</i> <sup>Y-&gt;C+</sup>	1/2	2/1	None to moderate lesions	1.0 (0-2)	3
	RW+ ( <i>Vkorc1</i> <sup>+/+</sup> )	0/0	4/4	No lesions	0	4
	Subtotals (N=)	6/7	6/5	-	-	-
<b>Females:</b>	RW	6/5	0/1	None to marked lesions	1.8 (0-3)	6
	<i>Vkorc1</i> <sup>Y-&gt;CY-&gt;C</sup>	4/4	0/0	Moderate to marked lesions	2.3 (2-3)	4
	<i>Vkorc1</i> <sup>Y-&gt;C+</sup>	2/1	0/1	None to moderate lesions	1.0 (0-2)	2
	RW+ ( <i>Vkorc1</i> <sup>+/+</sup> )	0/1	3/2	None to minimal lesions	0.3 (0-1)	3
	Subtotals (N=)	6/6	3/3	-	-	-

RW and RW+ designate the homozygous (*Vkorc1*<sup>Y->CY->C</sup>) and heterozygous (*Vkorc1*<sup>Y->C/+</sup>) warfarin-resistant and warfarin-susceptible phenotype, respectively.